Graft-versus-leukemia: no longer an epiphenomenon.

[1]  H. Sagara,et al.  Transfusion-associated graft-versus-host disease. , 1993, Fukushima journal of medical science.

[2]  M. Horowitz,et al.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose , 1993 .

[3]  B. Chapuis,et al.  Adoptive immunotherapy for recurrent CML after BMT. , 1993, Bone marrow transplantation.

[4]  P. Quesenberry,et al.  Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. , 1993, Blood.

[5]  R. Truitt,et al.  Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. , 1993, Bone marrow transplantation.

[6]  T. Smetsers,et al.  Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Szer,et al.  Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. , 1993, Bone marrow transplantation.

[8]  W. Wilmanns,et al.  Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. , 1993, Transplantation proceedings.

[9]  J. Radich,et al.  Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Barrett,et al.  T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. , 1993, Bone marrow transplantation.

[11]  J. Ferrara,et al.  Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.

[12]  R. Collins,et al.  Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. , 1992, Bone marrow transplantation.

[13]  J. Ritz,et al.  Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. , 1992, Blood.

[14]  A. Feinberg,et al.  Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. , 1991, The Journal of clinical investigation.

[15]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[16]  P. Martin.  Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. , 1991, Bone marrow transplantation.

[17]  L. Verdonck,et al.  Amplification of the graft-versus-leukemia effect in man by interleukin-2. , 1991, Transplantation.

[18]  S. Piantadosi,et al.  Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. , 1991, Blood.

[19]  S. Mackinnon,et al.  Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. , 1990, Blood.

[20]  C. Perreault,et al.  Minor histocompatibility antigens. , 1990, Blood.

[21]  S. Feig,et al.  Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.

[22]  K. Sullivan,et al.  Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. , 1990, Transplantation.

[23]  L. Barnett,et al.  Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. , 1990, Blood.

[24]  S. Smith,et al.  Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells. , 1990, Blood.

[25]  K. Offit,et al.  Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation. , 1990, Blood.

[26]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[27]  H. Heslop,et al.  Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. , 1989, Blood.

[28]  K. Sullivan,et al.  Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. , 1989, The New England journal of medicine.

[29]  W. Gregory,et al.  Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft‐versus‐leukaemia effect , 1988, British journal of haematology.

[30]  R. Hoffmann,et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. , 1988 .

[31]  J. Hank,et al.  Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial , 1985, Cancer.

[32]  R. Gale,et al.  HOW DOES BONE-MARROW TRANSPLANTATION CURE LEUKAEMIA? , 1984, The Lancet.

[33]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[34]  K. Sullivan,et al.  Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. , 1981, Transplantation proceedings.

[35]  G. Mathé,et al.  Adoptive immunotherapy of acute leukemia: experimental and clinical results. , 1965, Cancer research.

[36]  M. Tubiana,et al.  SUCCESSFUL ALLOGENIC BONE MARROW TRANSPLANTATION IN MAN: CHIMERISM, INDUCED SPECIFIC TOLERANCE AND POSSIBLE ANTI-LEUKEMIC EFFECTS. , 1965, Blood.

[37]  J. Loutit,et al.  Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.

[38]  J. Loutit,et al.  Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.

[39]  A. Nagler,et al.  Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. , 1992, Cancer investigation.

[40]  M. Horowitz,et al.  Second HLA-identical sibling transplants for leukemia recurrence. , 1992, Bone marrow transplantation.

[41]  D. Ginsburg,et al.  Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. , 1992, Blood.

[42]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[43]  D. Peakman,et al.  Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man? , 1978, Lancet.